USPTO serial 88369612
KALEIDO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 23, 2021
- Examiner
- LEIPZIG, MARC J
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with KALEIDO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Christina M. Licursi
Christina M. Licursi WOLF, GREENFIELD & SACKS, P.C.600 ATLANTIC AVENUEBOSTON, MA 02210-2206UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Preparations and substances for pharmaceutical and medical purposes, namely, for the treatment of dysbioses, inflammatory disorders and conditions, infectious diseases, metabolic diseases, nutritional disorders, malnutrition, immune-mediated diseases, including autoimmune diseases, allergies, and immune tolerance, malignancies and cancers, neurological diseases, psychiatric conditions, gastrointestinal diseases and disorders, gastrointestinal injury conditions, digestive abnormalities, dermatological conditions, cardiovascular diseases, nephrologic diseases and conditions, including organ failure, ophthalmic disorders, vaginal and penile conditions, pediatric disorders and conditions, including growth and developmental conditions, and geriatric disorders and conditions, all of the foregoing related to the microbiome and all of the foregoing excluding treatments for cystic fibrosis; therapeutic pharmaceuticals for medical use, namely, for the treatment of dysbioses, inflammatory disorders and conditions, infectious diseases, metabolic diseases, nutritional disorders, malnutrition, immune-mediated diseases, including autoimmune diseases, allergies, and immune tolerance, malignancies and cancers, neurological diseases, psychiatric conditions, gastrointestinal diseases and disorders, gastrointestinal injury conditions, digestive abnormalities, dermatological conditions, cardiovascular diseases, nephrologic diseases and conditions, including organ failure, ophthalmic disorders, vaginal and penile conditions, pediatric disorders and conditions, including growth and developmental conditions, and geriatric disorders and conditions, all of the foregoing related to the microbiome and all of the foregoing excluding treatments for cystic fibrosis | ACTIVE | Jul 8, 2020 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 23, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Mar 23, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 16, 2021 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Feb 15, 2021 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Feb 4, 2021 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jan 27, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 7, 2021 | IUAF | USE AMENDMENT FILED | — |
| Jan 7, 2021 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jul 9, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 7, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 7, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 7, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 7, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 12, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 12, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 23, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 10, 2019 | ALIE | ASSIGNED TO LIE | — |
| Oct 5, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 4, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 2, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 2, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 2, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 2, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 14, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 14, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 14, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 13, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 23, 2019 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Apr 22, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 6, 2019 | NWAP | NEW APPLICATION ENTERED | — |